COMP <GO>
OPK vs LBRX // EV/EBITDA & P/E VALUATION
OPKO Health Inc. (NASDAQ) VS. LB Pharmaceuticals Inc (NASDAQ) • 15-METRIC TALLY: OPK 2
— LBRX 3
■ METRIC PARITY
LAST: $1.66 (+2.47%) • MKT CAP: $1.24B
valuation
—
LAST: $40.15 (+0.80%) • MKT CAP: $1.30B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OPK VS. LBRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OPK | LBRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 33.90% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -10.20% | -8.40% | -1.80 | LBRX | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -14.41% | -2.72% | -11.69 | LBRX | /fcf-yield <GO> |
| Operating Margin | -19.30% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -14.90% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 2/9 | +2.00 | OPK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.9 | 52.9 | +5.92 | OPK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.24B | $1.30B | -$56.3M | LBRX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OPK REV | LBRX REV | OPK GROSS % | LBRX GROSS % | OPK FCF | LBRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $606.9M | $0 | 33.9% | — | -$178.5M | -$35.3M |
| FY 2024 | $713.1M | $0 | 30.6% | — | -$183.5M | -$53.8M |
| FY 2023 | $863.5M | — | — | — | -$28.2M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OPK // BETA —
LBRX // BETA —